EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?

Dana Hamadi iD, Suhail Saad-Omer, David Toro-Tobon, Marius N Stan

Thyroid® · 01.02.2026 · 36 (2) · 213-218

DOI: 10.1177/10507256251414948 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thyroid®, online erschienen am 13.01.2026. Verfasst von Dana Hamadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease, Antibodies, Monoclonal, Humanized, Skin Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pretibial dermopathy (PTD) is a rare, disfiguring manifestation of Graves’ disease. The shared pathophysiology with thyroid eye disease (TED), centered on fibroblast activation via a thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor (IGF-1R) complex, provides a strong rationale for using the IGF-1R inhibitor, teprotumumab.

Methods

We present a case series of five patients with severe PTD and concomitant TED who were treated with teprotumumab. A review of reported cases in the literature was also conducted.

Results

All patients experienced significant clinical improvement, including regression of skin thickening as well as enhanced functional capacity. Side effects included mild hearing loss, muscle cramps, and fatigue. One patient experienced a severe gastrointestinal event requiring treatment discontinuation, while those experiencing a recurrence of PTD, responded to a second course of therapy.

Conclusions

Teprotumumab showed promising efficacy in the treatment of PTD. Further studies are needed to confirm its durability and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyGraves DiseaseAntibodies, Monoclonal, HumanizedSkin DiseasesHumansFemaleMiddle AgedMaleTreatment OutcomeAdultReceptor, IGF Type 1Aged

Stichwörter der Autor:innen

Graves’ diseasepretibial dermopathyteprotumumabthyroid eye disease

Substanzen

teprotumumabAntibodies, Monoclonal, HumanizedReceptor, IGF Type 1

Autor:innen und Institutionen

  • Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN, USA.
  • Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Dana Hamadi

Zitieren

APA

Hamadi, D., Saad-Omer, S., Toro-Tobon, D., & Stan, M. N. (2026). Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?. Thyroid®, 36(2), 213-218. https://doi.org/10.1177/10507256251414948

Vancouver

Hamadi D, Saad-Omer S, Toro-Tobon D, Stan MN. Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?. Thyroid®. 2026;36(2):213-218. doi:10.1177/10507256251414948

BibTeX
@article{Hamadi2026,
  author = {Hamadi, Dana and Saad-Omer, Suhail and Toro-Tobon, David and Stan, Marius N},
  title = {Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?},
  journal = {Thyroid®},
  year = {2026},
  volume = {36},
  number = {2},
  pages = {213--218},
  doi = {10.1177/10507256251414948}
}
Kostenlos starten →